Randomized trial · people

Retatrutide: HbA1c down up to 1.94% in TRANSCEND-T2D-1

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In adults with type 2 diabetes on diet and exercise alone, all three retatrutide doses lowered HbA1c and body weight more than placebo over 40 weeks.

Kind
Randomized trial
Studied in
People
Number studied
537
Published
2026
Journal
Lancet

What they tested

The researchers asked whether retatrutide as the only diabetes medicine lowers HbA1c and body weight in adults whose type 2 diabetes stayed above target despite diet and exercise.

How the study was done

A randomized, double-blind, placebo-controlled phase 3 trial in 537 adults with type 2 diabetes, run across 48 clinics in three countries. Each person was assigned to one of three retatrutide doses (the 4 mg, 9 mg, and 12 mg arms) or to placebo (a dummy shot), given once a week under the skin for 40 weeks.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

Model. Individual results vary.

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

HbA1c (a 3-month average of blood sugar) changed by -1.69% in the 4 mg arm, -1.86% in the 9 mg arm, and -1.94% in the 12 mg arm, compared with -0.81% on placebo. Against placebo, the differences were -0.88%, -1.04%, and -1.12%, all p<0.0001. Body weight changed by -11.5%, -13.9%, and -15.3% across the three retatrutide arms, compared with -2.6% on placebo. The most common side effects were mostly mild to moderate stomach and gut problems that eased over time; 2-5% on retatrutide and 0% on placebo stopped treatment because of side effects, no severe low blood sugar was seen, and the 2 deaths, both in the 4 mg arm, were judged unrelated to the drug.

What it doesn’t show

The trial lasted 40 weeks, compared retatrutide only with placebo rather than other diabetes drugs, and included people with fairly recent diabetes (mean 2.5 years) using no other diabetes medicine. It was funded by Eli Lilly and Company.

The paper

Bajaj et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026.

The compound

More studies on Retatrutide

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking retatrutide? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo